 CAMBRIDGE, Mass., Sept. 23, 2021 GLOBE NEWSWIRE -- Beam Therapeutics Inc. Nasdaq: BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data highlighting advancements with the companys approach to developing novel lipid nanoparticle LNP formulations for in vivo liver editing. In addition, the company reported initial in vivo data demonstrating its delivery capabilities to tissues outside of the liver. The data will be presented today, September 23, 2021, from 11:15 11:45 a.m. ET at the TIDES USA Oligonucleotide Peptide Therapeutics Conference TIDES 2021 in a presentation titled Optimization of LNP for in vivo base editing. 